The limited availability and usage of pre-clinical laboratory instruments which provide biologically relevant data has resulted in unnecessarily high failure rates of pharmaceutical drug candidates in clinical trials, the single most expensive component of the pharmaceutical development process.
Teodor Aastrup et al. at Attana AB explain that the clinical results from Attana’s validated drug candidates have shown impressive progress in a short time and increased productivity in clinical trials.